SMH
AIMT

Sanders Morris Harris’s Aimmune Therapeutics AIMT Stock Holding History

Sanders Morris Harris’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-537,960
Closed -$8.99M – 282
2020
Q2 		$8.99M Buy
537,960
+196,710
+58% +$3.34M 4.37% 5
2020
Q1 		$5K Buy
+341,250
New +$8.72M ﹤0.01% 128
2019
Q4 		– Sell
-486,906
Closed -$10.2M – 307
2019
Q3 		$10.2M Buy
486,906
+225,800
+86% +$4.61M 2.47% 9
2019
Q2 		$5.44M Buy
+261,106
New +$5.38M 1.41% 11

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sanders Morris Harris's AIMT Position: Q3 2020 in Review

Sanders Morris Harris sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 537,960 shares — an estimated $8.99M sold.

Sanders Morris Harris first reported a position in AIMT in Q2 2019 and held it in 4 quarters. The position peaked at $10.2M in Q3 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Sanders Morris Harris reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Sanders Morris Harris sold 537,960 Aimmune Therapeutics shares in Q3 2020, an estimated $8.99M.
  • Sanders Morris Harris first reported a position in Aimmune Therapeutics in Q2 2019 and held it in 4 quarters.
  • Sanders Morris Harris's Aimmune Therapeutics position peaked at $10.2M in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Sanders Morris Harris's 13F filing for Q3 2020, filed 16 Oct 2020.